Corvus Pharmaceuticals (CRVS) Total Non-Current Liabilities (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Total Non-Current Liabilities of $143000.0 for Q1 2026, down 71.57% year-over-year from $503000.0 in Q1 2025, and down 37.55% quarter-over-quarter from $229000.0 in Q4 2025.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $143000.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 71.57% year-over-year to $143000.0; the TTM figure through Mar 2026 stood at $143000.0 (down 71.57% YoY), while the FY2025 annual figure was $229000.0, down 61.38% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $143000.0, down from $229000.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.0 million in Q2 2022, with the low at $143000.0 in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $610000.0 (2024), against an average of $619875.0.
- The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities surged 838.1% in 2022, then sank 71.57% in 2026.
- Corvus Pharmaceuticals' Total Non-Current Liabilities stood at $985000.0 in 2022, then plunged by 34.21% to $648000.0 in 2023, then slipped by 8.49% to $593000.0 in 2024, then tumbled by 61.38% to $229000.0 in 2025, then tumbled by 37.55% to $143000.0 in 2026.
- Business Quant data shows CRVS's Total Non-Current Liabilities at $143000.0 in Q1 2026, $229000.0 in Q4 2025, and $321000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - | 59,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 59,000.00 |
| Mar 31, 2026 | 143,000.00 |
| Dec 31, 2025 | 229,000.00 |
| Sep 30, 2025 | 321,000.00 |
| Jun 30, 2025 | 414,000.00 |
| Mar 31, 2025 | 503,000.00 |
| Dec 31, 2024 | 593,000.00 |
| Sep 30, 2024 | 625,000.00 |
| Jun 30, 2024 | 531,000.00 |
| Mar 31, 2024 | 595,000.00 |
| Dec 31, 2023 | 648,000.00 |
| Sep 30, 2023 | 686,000.00 |
| Jun 30, 2023 | 773,000.00 |
| Mar 31, 2023 | 903,000.00 |
| Dec 31, 2022 | 985,000.00 |
| Sep 30, 2022 | 945,000.00 |
| Jun 30, 2022 | 1.02 Mn |
| Dec 31, 2021 | 105,000.00 |
| Dec 31, 2018 | 7.03 Mn |
| Sep 30, 2018 | 7.75 Mn |